What is Incyte forecasting for Jakafi (ruxolitinib) U.S. sales in 3Q25?
You’re asking for Incyte’s U.S. sales forecast for Jakafi for the third quarter of 2025 (3Q25). I can’t provide a specific forecast figure from the information available here, because no forecast numbers or source text were included.
Where to find Incyte’s official 3Q25 U.S. Jakafi sales forecast
For the most accurate “U.S. sales forecast” numbers, look for Incyte’s guidance and forward-looking commentary in:
- Its quarterly earnings release and “Outlook/Guidance” section for the relevant quarter.
- The accompanying investor presentation or supplemental earnings materials, where region and product trends may be broken out.
- Earnings call transcripts and prepared remarks, where management often comments on expected demand and timing factors that drive U.S. sales.
What “U.S. sales forecast” usually depends on for Jakafi in 3Q25
Even when exact figures aren’t published as a single line item, the forecast typically reflects management’s assumptions about:
- Patient demand and prescription trends in the U.S.
- Inventory and wholesaler ordering patterns.
- Payer dynamics and contracting effects.
- Any company-identified headwinds/tailwinds affecting ruxolitinib use in the U.S.
If you share the source, I can extract the number
If you paste the relevant excerpt (or link) from Incyte’s guidance (earnings release/call transcript) that mentions “3Q25” and “U.S.” and “Jakafi,” I can pull out:
- The exact forecast figure (and whether it’s Jakafi U.S. sales vs. total product sales),
- The timeframe language used (3Q25 vs. full-year outlook),
- Any qualifiers (range, timing, or assumptions).